Using Tykerb (lapatinib; GlaxoSmithKline, U.K.) and Herceptin (trastuzumab; Genentech, South San Francisco, Calif.) anti-HER-2 drugs together doubles the odds of recovery compared to either drug alone in HER-2 positive early breast cancer patients, reports NeoALTTO trial investigators in the January 17th online publication at Lancet Oncology journal homepage. This study provides a proof-of-concept that dual HER-2 block is better than using a single agent HER-2 blocker.
Oncology targets, strategies, cancer drug development and personalized medicine
Showing posts with label paclitaxel. Show all posts
Showing posts with label paclitaxel. Show all posts
Thursday, January 19, 2012
Wednesday, October 13, 2010
Old Drugs have a lot more Firepower
Celgene Corporation (NASDAQ:CELG) was in the news a few months ago for buying Abraxis BioScience for 2.9 billion (read: A Billionaire’s Biotech Deal And Old Drugs Reborn at forbes.com, or Prominent Drug Chief to Sell Abraxis BioScience to Celgene for $2.9 Billion at nytimes.com) With this purchase, Celgene has become a big player in the Oncology biz-space with two re-incarnated drugs:
Subscribe to:
Posts (Atom)